Currently, there are 1.01B common shares owned by the public and among those 1.01B shares have been available to trade.
The company’s stock has a 5-day price change of 3.00% and 3.77% over the past three months. EXC shares are trading 17.59% year to date (YTD), with the 12-month market performance up to 14.60% higher. It has a 12-month low price of $34.01 and touched a high of $48.11 over the same period. EXC has an average intraday trading volume of 8.76 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -2.36%, -1.96%, and 8.34% respectively.
Institutional ownership of Exelon Corp (NASDAQ: EXC) shares accounts for 85.22% of the company’s 1.01B shares outstanding.
It has a market capitalization of $44.68B and a beta (3y monthly) value of 0.37. The stock’s trailing 12-month PE ratio is 16.42, while the earnings-per-share (ttm) stands at $2.70. The company has a PEG of 2.63 and a Quick Ratio of 0.98 with the debt-to-equity ratio at 1.76. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.02% over the week and 1.86% over the month.
Analysts forecast that Exelon Corp (EXC) will achieve an EPS of 0.46 for the current quarter, 0.73 for the next quarter and 2.82 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0.37 while analysts give the company a high EPS estimate of 0.37. Comparatively, EPS for the current quarter was 0.47 a year ago. Earnings per share for the fiscal year are expected to increase by 7.97%, and 4.57% over the next financial year. EPS should grow at an annualized rate of 6.24% over the next five years, compared to -4.04% over the past 5-year period.
Looking at the support for the EXC, a number of firms have released research notes about the stock. KeyBanc Capital Markets stated their Underweight rating for the stock in a research note on May 14, 2025, with the firm’s price target at $39. Evercore ISI coverage for the Exelon Corp (EXC) stock in a research note released on April 15, 2025 offered a In-line rating with a price target of $48. Guggenheim was of a view on January 23, 2025 that the stock is Buy, while Evercore ISI gave the stock Outperform rating on January 21, 2025, issuing a price target of $43- $44. Jefferies on their part issued Buy rating on September 20, 2024.
